Salim Dhanji
Chief Executive Officer presso ME THERAPEUTICS HOLDINGS INC.
Patrimonio netto: 14 M $ in data 31/03/2024
Profilo
Salim Zulifkar Dhanji is currently the Chief Executive Officer & Executive Director at ME Therapeutics Holdings, Inc. since 2023 and the President at Perceptive Property Development since 2013.
He previously worked as the Director-Preclinical Research at Qu Biologics, Inc. from 2009 to 2014.
Dr. Dhanji received his undergraduate degree in 2001 and his doctorate in 2006 from the University of British Columbia.
Partecipazioni note in società pubbliche
| Società | Data | Numero di azioni | Valorizzazione | Data di valutazione |
|---|---|---|---|---|
| 05/02/2024 | 4 175 143 ( 17.72% ) | 14 M $ | 31/03/2024 |
Posizioni attive di Salim Dhanji
| Società | Posizione | Inizio |
|---|---|---|
| ME THERAPEUTICS HOLDINGS INC. | Chief Executive Officer | 09/03/2023 |
Precedenti posizioni note di Salim Dhanji
| Società | Posizione | Fine |
|---|---|---|
Qu Biologics, Inc.
 Qu Biologics, Inc. BiotechnologyHealth Technology Qu Biologics, Inc. develops site specific immunomodulators that aim to restore the body's innate immune system to treat cancer. The firm specializes in ulcerative colitis, Crohn's disease, arthritis, cancer, autoimmune diseases, autoimmune disorders, inflammatory bowel disease, IBD, Site Specific Immunomodulators, immunotherapies, investigational drug, auto-immune, pharmaceuticals, research, inflammation, biotech and clinical trials. The company was founded by Harold David Gunn and Rob Freeman in 2007 and is headquartered in Burnaby, Canada. | Corporate Officer/Principal | 01/01/2014 |
Formazione di Salim Dhanji
| University of British Columbia | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 1 |
|---|---|
| ME THERAPEUTICS HOLDINGS INC. | Health Technology |
| Aziende private | 1 |
|---|---|
Qu Biologics, Inc.
Qu Biologics, Inc. BiotechnologyHealth Technology Qu Biologics, Inc. develops site specific immunomodulators that aim to restore the body's innate immune system to treat cancer. The firm specializes in ulcerative colitis, Crohn's disease, arthritis, cancer, autoimmune diseases, autoimmune disorders, inflammatory bowel disease, IBD, Site Specific Immunomodulators, immunotherapies, investigational drug, auto-immune, pharmaceuticals, research, inflammation, biotech and clinical trials. The company was founded by Harold David Gunn and Rob Freeman in 2007 and is headquartered in Burnaby, Canada. | Health Technology |
- Borsa valori
- Insiders
- Salim Dhanji
